fig11

Figure 11. (A) Schematic illustration of the preparation and mechanism of CB[7]-based nanomedicine (PG-Pt-LA/CB[7]) in overcoming drug resistance of CRC cells; (B) Changes of F. nucleatum levels in CRC cells with different treatments; (C) Changes of tumor volume in tumor-bearing mice with different formulations (^**P < 0.01, ^***P < 0.001). This figure is quoted with permission from Yan et al.^[144]. CRC: Colorectal cancer.